论文信息 - Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). - 字舞流文

Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL).

M. Baccarani | H. Kantarjian | J. Cortes | H. Khoury | E. Leip | C. Gambacorti-Passerini | M. Zanichelli | A. Zaritskey | N. Besson | V. Kelly | T. Brummendorf | J. Milone | D. Kim | P. Dorlhiac-Llacer | J. Navarro | A. Rapoport